Recombinant Herpes Zoster Vaccine

Phase 3Vaccine

Recombinant Herpes Zoster Vaccine is one of 68 biologic programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Herpes ZosterRecruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Herpes ZosterPhase 3

Recruiting

Competition

Competitive Landscape

147 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Primacor

Geodon

Cardene

Sun Pharmaceutical Industries, Inc.

Approved

—4

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—5

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Midamor

Giapreza

LLa Jolla Pharmaceutical Company

Colcrys

1 9

Pelacarsen

Novartis

Phase 3

1 10

Cagrilintide

Novo Nordisk

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Herpes Zoster

NCT06088745

Q2 2029

ApprovedActive, not recruiting

Cardiovascular Disease

NCT07485283

Q2 2032

Post-ApprovalActive, not recruiting

Rheumatic Disease

NCT05879419

Clinical

Trials by Indication[1]

Herpes Zoster1 trial

A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine

Recruiting·BBeijing Luzhu Biotechnology Co., Ltd.·Phase 3·NCT06088745·4 enrolled

Rheumatic Disease1 trial

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases

Active, not recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT05879419·2,005 enrolled

Cardiovascular Disease1 trial

A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above

Active, not recruiting·TTor Biering-Sørensen·Approved·NCT07485283·168,460 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Recombinant Herpes Zoster Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Herpes Zoster Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Herpes Zoster Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Luzhu Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: BBeijing Luzhu Biotechnology Co., Ltd.

Recombinant Herpes Zoster Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2029

Q2 2032

Trials by Indication[1]

Herpes Zoster1 trial

Rheumatic Disease1 trial

Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News